


Priority and watchlist medicines for in-licensing by the Medicines Patent Pool



HIV

lenacapavir *Gilead*

broadly neutralising antibodies for HIV post-natal prophylaxis

Multiple patent holders

cabotegravir & rilpivirine *ViiV & Janssen*

doravirine *MSD*

islatravir *Merck*



TUBERCULOSIS

quabodepistat *Otsuka*

BTZ-043 *Univ. of Munich & DZIF*

delpazolid *LegoChem BioSciences*

ganfeborole *GSK*

macozinone *EPFL*

sudapyridine *Shanghai Jiatan Biotech*



PANDEMIC & EPIDEMIC THREATS

baloxavir marboxil *Roche*



VIRAL HEPATITIS

bulevirtide *Gilead*



DIABETES, CARDIOVASCULAR & METABOLIC DISORDERS

Incretin-based therapies (incl. GLP1 RA)

Multiple patent holders

including

oral semaglutide *Novo Nordisk*

cardiovascular fixed-dose combination therapies

Multiple patent holders



CHILDHOOD ONSET DISEASES

RESPIRATORY SYNCYTIAL VIRUS

nirsevimab *Astrazeneca/Sanofi*

clesrovimab *MSD*

SICKLE CELL DISEASE

voxelotor *Pfizer*

CYSTIC FIBROSIS

elexacaftor/tezacaftor/ivacaftor *Vertex*



ONCOLOGY

LUNG CANCER

aumolertinib

Revolution Medicines

osimertinib *Astrazeneca*

adagrasib *Mirati*

lazertinib *Janssen*

sotorasib *Amgen*

BREAST CANCER

abemaciclib *Eli Lilly*

ribociclib *Novartis*

trastuzumab SQ *Roche*

HAEMATOLOGICAL MALIGNANCIES

ibrutinib *Janssen*

zanubrutinib *Beigene*

PROSTATE CANCER

apalutamide *Janssen*

darolutamide *Bayer*

MULTIPLE CANCER INDICATIONS

Immune checkpoint inhibitors

Multiple patent holders

including

pembrolizumab *MSD*

oral paclitaxel / encequidar

Athenex

PRIORITY LIST

WATCHLIST

MAY 2024